Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 11/20 | 0.36 |
| ▸ | CTSL | P07711 | 7/20 | 0.36 |
| ▸ | CTSS | P25774 | 7/20 | 0.36 |
| ▸ | CTSB | P07858 | 5/20 | 0.36 |
| ▸ | CTSV | O60911 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7424838 | 0.85 | CTSK (0.34) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL6765318 | 0.85 | CTSK (0.36) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL7246379 | 0.84 | — | — | |
| SCHEMBL6594359 | 0.82 | CTSK (0.33) | CTSKCTSLCTSS | |
| SCHEMBL5099273 | 0.82 | CTSK (0.40) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL5092868 | 0.81 | CTSK (0.35) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL4767047 | 0.81 | CTSK (0.42) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL4839956 | 0.81 | CTSK (0.40) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL6404947 | 0.80 | CTSK (0.44) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL5098737 | 0.80 | ALDH1A1 (0.41) | CTSKCTSLCTSSCTSBCTSV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1307204-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2004-06-02 | — | — | EP | disclosed |
| US-20040002487-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2004-01-01 | — | — | US | disclosed |
| EP-1307204-A1 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2003-05-07 | — | — | EP | disclosed |
| US-20030044399-A1 | Method of treatment | SMITHKLINE BEECHAM CORPORATION | 2003-03-06 | — | — | US | disclosed |
| WO-2001095911-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030044399-A1 | Method of treatment | DNPEP, PEPD, ANPEP | CTSK 47/4885CTSL 20/4885CTSS 15/4885 |
| US-20040002487-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | CTSK 1/4885CTSL 25/4885CTSS 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.